Corporate InformationCorporate Profile
- Name
- Human Life CORD Japan Inc.
- Incorporation
- April 5, 2017
- Address
- [Headquarters]
1-9-10, Nihonbashi-horidomecho, Chuo-ku, Tokyo, Japan
Nihonbashi Life Science Building 7, 5F
[TIP lab]
National University Corporation Tokyo Medical and Dental University
1-5-45 Yushima, Bunkyo-ku, Tokyo, JAPAN - Executives
-
President and Representative Director (CEO) Masamitsu Harata
Director Nobutoshi Matsushita
Outside Director Tetsuo Yamanaka
Outside Director Hiroshi Ishiai
Outside Director Misao Konishi
Outside Director Takaaki Nakajima
Outside Auditor (Full time) Hiroshi Nakamura
Outside Auditor (Part-time) Daisuke Fujioka
Outside Auditor (Part-time) Maya Ito - Senior Advisor
-
Kazuo Asakawa (Corporate Strategy)
Yoshihiro Kidachi (Corporate Strategy)
Hirotaka Yabuki (Corporate Strategy)
Andy C. Ye (Global Strategy)
Keiya Ozawa (Medical)
Tokiko Nagamura (Medical)
Satoshi Teramukai (Biostatistics) - Number of employees (including temporary staff)
- 24 (as of January 2024)
- Business Activities
- R&D, manufacturing, and sales of regenerative medicine products
- Capital accounts
- 2.07 billion yen
- Cooperative organizations
-
◆Academia
The Institute of Medical Science, the University of Tokyo
National University Corporation Tokyo Medical and Dental University
Jichi Medical University
◆Business Affiliates
Inabata & Co., Ltd.
Rohto Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd.
Alfresa Corporation
Alfresa Holdings Corporation
AutoPhagyGO
◆Independent Auditors
EY Ernst & Young ShinNihon LLC - Member organizations
-
LINK-J https://www.link-j.org/
ME-BYO http://www.pref.kanagawa.jp/docs/cz6/me-byokaizen/
JSRM https://www.jsrm.jp/
FIRM https://firm.or.jp/
JPA https://nanbyo.jp/ - Banks
-
Mizuho Bank, Marunouchi Chuo Branch
Sumitomo Mitsui Banking Corporation, Nihonbashi Branch
Kiraboshi Bank, Shinbashi Branch
Corporate InformationHistory
- 2017
-
Human Life CORD Japan Inc. established in Chiyoda-ku, Tokyo
Entered into a business alliance with Tissue Genesis
Concluded a joint research agreement with the Institute of Medical Science, the University of Tokyo
Concluded a joint research agreement with Kansai Medical University
Began sales of Tissue Genesis products - 2018
-
Transfer offices to Chuo-ku, Tokyo. (LINK-J member)
First employee joined the company
Concluded an exclusive sales agent agreement with Inabata & Co., Ltd.
- 2019
-
Concluded a license agreement with the University of Tokyo
First-class medical device manufacturing and sales business license obtained
Concluded a joint R&D contract with StemMed
Entered into a capital and business alliance with Alfresa Holdings Corporation
Entered into a capital alliance with Rohto Pharmaceutical Co., Ltd.
Received Tokyo Metropolitan Governor's Award for Excellence at the Tokyo Venture Company Championship - 2020
-
Procured a total of ¥1.1 billion through a capital increase through a third-party allocation of shares
Transitioned to a company with statutory auditors
Study initiation for acute respiratory distress syndrome (ARDS) associated with COVID-19
Selected for AMED "Therapeutic Drug Development for COVID-19"
Established "Human Life CORD Applied Cellular Medicine Laboratory" at Nagoya University
Concluded a joint research agreement with the Institute of Medical Science, the University of Tokyo regarding the establishment of a stable supply system - 2021
-
Concluded a joint research agreement with the Institute of Medical Science, the University of Tokyo for the treatment of progeria (Werner's Syndrome)
Launch of IMSUT-HLC Cell Processing Facility, a cell processing manufacturing facility - 2022
-
Procured a total of 854 million yen through a third-party allocation of shares
Concluded a manufacturing outsourcing agreement with Rohto Pharmaceutical Co., Ltd.
End of "Human Life CORD Applied Cellular Medicine Laboratory" at Nagoya University
Initiation of clinical trials for non-infectious pulmonary complications after hematopoietic stem cell transplantation - 2023
-
Awarded by the Ministry of Health, Labor and Welfare by the Cabinet Office for the 5th Japan Open Innovation Award.
Concluded a joint business agreement with Mochida Pharmaceutical “HLC-001” Co., Ltd. on “HLC-001”
Selected as a startup support program "J-Startup" by the Ministry of Economy, Trade and Industry
Concluded a joint research agreement with Tokyo Medical and Dental University on recalcitrant autoimmune diseases
Corporate Information
Back to Top Page